氨甲环酸在乳房手术中的术式特异性疗效:5,202例倾向性评分调整分析
该回顾性队列纳入2019-2025年单中心私立医院5,202例乳房手术,采用逆概率治疗加权控制混杂。氨甲环酸在缩乳术(OR 0.28,95%CI 0.14-0.58,P<0.001,NNT=20)和乳房切除后乳房固定术(OR 0.42,95%CI 0.20-0.88,P<0.001)显著降低血肿,初次隆乳未见统计学差异。
要点
- 缩乳术使用氨甲环酸血肿率2.2% vs 7.2%,OR 0.28,NNT=20。
- 乳房固定术联合假体取出血肿率1.6% vs 6.0%,OR 0.42。
- 初次隆乳血肿率1.2% vs 1.2%,OR 0.94,无统计学差异。
核心结论
- 氨甲环酸疗效具有术式依赖性,在缩乳术和涉及广泛腺体切除的乳房固定术中提供显著血肿保护,初次隆乳无统计学可检测获益。
研究设计与样本
- 回顾性队列研究,纳入2019-2025年单中心私立医院多术者连续5,202例手术:初次隆乳3,738例、缩乳术943例、假体取出联合乳房固定术358例、单纯假体取出163例。
- 采用逆概率治疗加权控制时间采纳偏倚和混杂因素,氨甲环酸由术者酌情决定。
主要发现
- 氨甲环酸使用率从2019年7.0%升至2025年93.0%,协变量平衡后所有SMD<0.2。
- 缩乳术血肿需手术干预率2.2% vs 7.2%,调整OR 0.28(95%CI 0.14-0.58,P<0.001),NNT=20。
- 假体取出联合乳房固定术血肿率1.6% vs 6.0%,OR 0.42(95%CI 0.20-0.88,P<0.001)。
- 初次隆乳血肿率1.2% vs 1.2%,OR 0.94(95%CI 0.36-2.42,P=0.905),与假体平面无关。
- 无血栓栓塞事件发生;手术部位感染OR 0.47(P=0.02)但事件数少且缺乏合理生物学机制,应视为探索性。
关键数值与推荐
- 主要结局为30天内需手术干预的血肿,未触及积液的孤立性瘀斑不归类为血肿。
- 缩乳术:TXA组血肿2.2% vs 非TXA组7.2%,调整OR 0.28(95%CI 0.14-0.58,P<0.001),NNT=20。
- 假体取出联合乳房固定术:血肿1.6% vs 6.0%,OR 0.42(95%CI 0.20-0.88,P<0.001)。
- 初次隆乳:血肿1.2% vs 1.2%,OR 0.94(95%CI 0.36-2.42,P=0.905)。
临床怎么用
- 支持术式特异性实践指导而非普遍预防性使用氨甲环酸。
- 在缩乳术和涉及广泛腺体切除的乳房固定术中可考虑使用氨甲环酸降低血肿风险。
- 初次隆乳中氨甲环酸的血肿预防获益未达统计学显著,不应常规以降低血肿为目的使用。
局限性
- 回顾性队列设计,氨甲环酸使用由术者酌情决定,可能存在选择偏倚。
- 单中心私立医院数据,外推性受限。
- 手术部位感染差异事件数少且缺乏合理生物学机制,应视为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hematoma remains a major complication following breast surgery. While tranexamic acid (TXA) efficacy is established in reduction mammaplasty, its utility across other breast procedures remains unclear. METHODS: This retrospective cohort study included 5,202 consecutive procedures (2019-2025) performed by multiple surgeons at a single private hospital: primary augmentation (n=3,738), reduction mammaplasty (n=943), explantation with mastopexy (n=358), and explantation alone (n=163). TXA administration was at surgeon discretion. Inverse Probability of Treatment Weighting controlled for temporal adoption bias and confounders. Primary outcome was hematoma requiring surgical intervention within 30 days; isolated ecchymosis without palpable collection was not classified as hematoma. RESULTS: TXA adoption increased from 7.0% (2019) to 93.0% (2025). After achieving covariate balance (all SMD <0.2), procedure-specific effects emerged. In reduction mammaplasty, TXA significantly reduced hematoma (2.2% vs 7.2%; adjusted OR 0.28, 95% CI 0.14-0.58, p<0.001; NNT=20). Explantation with mastopexy showed similar benefit (1.6% vs 6.0%; OR 0.42, 95% CI 0.20-0.88, p<0.001). Primary augmentation demonstrated no statistically detectable difference (1.2% vs 1.2%; OR 0.94, 95% CI 0.36-2.42, p=0.905), regardless of implant plane. No thromboembolic events occurred. Surgical site infection showed a nominally significant difference (OR 0.47, p=0.02) but should be considered exploratory given small event counts and absence of a plausible biological mechanism. Seroma and wound dehiscence showed no significant differences. CONCLUSIONS: TXA efficacy is procedure-dependent. It provides significant protection in reduction mammaplasty and mastopexy involving extensive parenchymal dissection, but shows no statistically detectable benefit in primary augmentation. These findings support procedure-specific practice guidance rather than universal prophylaxis.
引用
- Friedman O, Maiershon D, Paniri Y, et al. Procedure-Specific Efficacy of Tranexamic Acid in Breast Surgery: A Propensity-Score Adjusted Analysis of 5,202 Procedures. Plast Reconstr Surg. 2026. PMID: 42154472. doi:10.1097/PRS.0000000000013206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。